Bioequivalence Clinical Trial
Official title:
Single Dose, Full Replicate, Crossover Comparative Bioavailability Study of Telmisartan 80 mg Tablets in Healthy Male and Female Volunteers / Fasting State
This single center, randomized, single dose, full replicate, crossover comparative laboratory-blinded study will be conducted in healthy male and female volunteers in order to determine the bioequivalence of two different formulations of telmisartan 80 mg tablets after oral administration under fasting conditions.
The study is characterized by single center, randomized, single dose, laboratory-blinded,
4-period, 2-sequence, full replicate crossover design.The objective is to determine the
bioequivalence of two different formulations of telmisartan after a single oral dose
administration under fasting conditions. The test product is Telmisartan 80 mg tablets
manufactured by Pharmtechnology LLC, Belarus. The reference product is Micardis 80 mg tablets
manufactured by Boehringer Ingelheim Ellas AE, Greece. The primary study endpoints are the
pharmacokinetic parameters Cmax and AUC0-T of telmisartan.
Eligible 26 healthy adult subjects will be randomized to the one of two predetermined
sequences: ABAB or BABA where A = the test product, B = the reference product. Clinical part
of the study will include 4 periods; in each of them a single 80 mg dose of telmisartan will
be administered orally with approximately 240 mL of water, in the morning, following a
10-hour overnight fast. Wash-out period between treatment administrations will last at least
14 calendar days.
Subjects will be confined to the clinical site from at least 10 hours prior to each drug
administration until 24 hours following each drug administration. Subjects will return to the
clinical site for the remaining blood samples.
In each study period, 21 blood samples will be collected for pharmacokinetic assessments. The
first blood sample will be collected prior to drug administration while the others will be
collected up to 72 hours after drug administration (0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25,
1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 postdose)
.
Total study duration: up to 74 days (including screening).
Telmisartan plasma concentrations will be measured by a validated bioanalytical method.
Statistical analysis of pharmacokinetic parameters will be based on an ANOVA model. Two-sided
90% confidence interval of the ratio of geometric LSmeans will be obtained from the
ln-transformed pharmacokinetic parameters.
Statistical inference of telmisartan will be based on a bioequivalence approach using the
following standards:
- average bioequivalence (the ratio of geometric LSmeans with corresponding 90% confidence
interval calculated from the exponential of the difference between the test and the
reference product for the ln-transformed parameters Cmax and AUC0-T should all be within
the 80.00 to 125.00% bioequivalence range);
- scaled-average-bioequivalence (in the event that the Cmax reference-to-reference
within-subject CV is greater than 30%, that its test-to-reference geometric LSmeans
ratio is within the bioequivalence range of 80.00 125.00% and the average bioequivalence
criteria are not met, a scaling approach to the bioequivalence assessment will be used).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04938856 -
Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03646331 -
Bioequivalence of Imeglimin Tablet Formulations
|
Phase 1 | |
Completed |
NCT04564456 -
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05197517 -
Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition
|
Phase 1 | |
Completed |
NCT03702894 -
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Withdrawn |
NCT02894515 -
Bioequivalence Study of Idalopirdine in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03018015 -
Ibuprofen Bioavailability Trial With Oral Single Dose Administration.
|
Phase 1 | |
Completed |
NCT02206295 -
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
|
Phase 1 | |
Completed |
NCT01331993 -
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
|
Phase 1 | |
Completed |
NCT01260805 -
A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
|
Phase 1 | |
Recruiting |
NCT06066112 -
Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
|
Phase 1 | |
Completed |
NCT05477810 -
Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions
|
Early Phase 1 | |
Completed |
NCT04546256 -
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05083325 -
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
|
Phase 1 | |
Completed |
NCT05061901 -
Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT04138888 -
A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT05145621 -
Oral Bio-equivalence Study
|
Phase 1 | |
Completed |
NCT06124560 -
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
|
Phase 1 | |
Completed |
NCT03340753 -
Bioavailability of KBP-5074 Tablet vs Capsule Formulations
|
Phase 1 | |
Completed |
NCT04230070 -
Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product
|
Phase 1 |